Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome
Fuente:
Wiley Open Access
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artículo Open Access |
| Pubblicazione: |
Wiley
2025
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1867020078453620736 |
|---|---|
| author | Chunxiang Xu Xingyu Qiu Nan Xu Gensheng Zhang Enyin Lai Liang Zhao |
| author_facet | Chunxiang Xu Xingyu Qiu Nan Xu Gensheng Zhang Enyin Lai Liang Zhao Chunxiang Xu Xingyu Qiu Nan Xu Gensheng Zhang Enyin Lai Liang Zhao |
| collection | Wiley Open Access |
| contents | Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome Chunxiang Xu Xingyu Qiu Nan Xu Gensheng Zhang Enyin Lai Liang Zhao Experimental Physiology Abstract The antihypertensive mechanism of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin–angiotensin–aldosterone system, sympathetic nervous system suppression, ion homeostasis restoration, anti‐inflammatory/antioxidant actions, weight loss and improved vascular function. These synergistic pathways collectively reduce blood pressure and provide cardiorenal protection in cardiovascular–kidney–metabolic (CKM) syndrome patients. Elucidating these multi‐target antihypertensive effects holds critical implications for optimizing therapeutic strategies, mitigating cardiorenal risks and establishing SGLT2 inhibitors as adjunctive antihypertensive therapy in CKM syndrome patients. 10.1113/ep092813 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1113/ep092813 |
| format | Artículo Open Access |
| id | wiley_oa_10_1113_ep092813 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome Chunxiang Xu Xingyu Qiu Nan Xu Gensheng Zhang Enyin Lai Liang Zhao Experimental Physiology Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome Chunxiang Xu Xingyu Qiu Nan Xu Gensheng Zhang Enyin Lai Liang Zhao Experimental Physiology Abstract The antihypertensive mechanism of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin–angiotensin–aldosterone system, sympathetic nervous system suppression, ion homeostasis restoration, anti‐inflammatory/antioxidant actions, weight loss and improved vascular function. These synergistic pathways collectively reduce blood pressure and provide cardiorenal protection in cardiovascular–kidney–metabolic (CKM) syndrome patients. Elucidating these multi‐target antihypertensive effects holds critical implications for optimizing therapeutic strategies, mitigating cardiorenal risks and establishing SGLT2 inhibitors as adjunctive antihypertensive therapy in CKM syndrome patients. 10.1113/ep092813 http://creativecommons.org/licenses/by/4.0/ |
| title | Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome |
| topic | Experimental Physiology |
| url | https://physoc.onlinelibrary.wiley.com/doi/10.1113/EP092813 |